JP2024546138A5 - - Google Patents
Info
- Publication number
- JP2024546138A5 JP2024546138A5 JP2024535372A JP2024535372A JP2024546138A5 JP 2024546138 A5 JP2024546138 A5 JP 2024546138A5 JP 2024535372 A JP2024535372 A JP 2024535372A JP 2024535372 A JP2024535372 A JP 2024535372A JP 2024546138 A5 JP2024546138 A5 JP 2024546138A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289501P | 2021-12-14 | 2021-12-14 | |
| US63/289,501 | 2021-12-14 | ||
| PCT/CA2022/051797 WO2023108260A1 (en) | 2021-12-14 | 2022-12-08 | Tryptamine prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546138A JP2024546138A (ja) | 2024-12-17 |
| JPWO2023108260A5 JPWO2023108260A5 (https=) | 2025-12-24 |
| JP2024546138A5 true JP2024546138A5 (https=) | 2025-12-24 |
Family
ID=86775179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535372A Pending JP2024546138A (ja) | 2021-12-14 | 2022-12-08 | トリプタミンプロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250051278A1 (https=) |
| EP (1) | EP4448489A4 (https=) |
| JP (1) | JP2024546138A (https=) |
| CN (1) | CN118679146A (https=) |
| CA (1) | CA3240633A1 (https=) |
| WO (1) | WO2023108260A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| CN115867533B (zh) * | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| EP4263504A4 (en) * | 2020-12-18 | 2025-05-14 | COMPASS Pathfinder Limited | Modified indole alkaloids for therapeutic uses |
-
2022
- 2022-12-08 JP JP2024535372A patent/JP2024546138A/ja active Pending
- 2022-12-08 EP EP22905564.5A patent/EP4448489A4/en active Pending
- 2022-12-08 US US18/719,620 patent/US20250051278A1/en active Pending
- 2022-12-08 CA CA3240633A patent/CA3240633A1/en active Pending
- 2022-12-08 WO PCT/CA2022/051797 patent/WO2023108260A1/en not_active Ceased
- 2022-12-08 CN CN202280082458.9A patent/CN118679146A/zh active Pending